Diane Knapp
Adult Health · Beaver, PANPI 1912090499
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 472 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 472 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$1K
- AbbVie$962
- AstraZeneca$767
- Lilly USA, LLC$729
- Novo Nordisk$531
- Amgen$427
- plus $5K from 34 others
What the payments were for
- Food & beverage$9,542100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 49 | $1,223 |
| AbbVie | 41 | $962 |
| AstraZeneca(2 entities) | 39 | $767 |
| Lilly USA, LLC | 51 | $729 |
| Novo Nordisk | 35 | $531 |
| Amgen(2 entities) | 17 | $427 |
| Medtronic | 19 | $360 |
| Merck | 20 | $345 |
| GSK | 14 | $294 |
| Novartis | 13 | $291 |
| Corcept Therapeutics | 11 | $272 |
| Johnson & Johnson | 15 | $258 |
| Amarin Pharma, Inc. | 13 | $244 |
| Xeris Pharmaceuticals, Inc. | 13 | $241 |
| Currax Pharmaceuticals LLC | 14 | $235 |
| Bayer | 11 | $215 |
| Astellas Pharma US Inc | 6 | $177 |
| Abbott | 8 | $176 |
| Dexcom, Inc. | 8 | $168 |
| Pfizer | 8 | $165 |
| Madrigal Pharmaceuticals | 4 | $161 |
| Esperion Therapeutics, Inc. | 7 | $145 |
| Evoke Pharma, Inc. | 7 | $140 |
| Vivus LLC | 7 | $140 |
| Amphastar Pharmaceuticals, Inc. | 5 | $114 |
| Sanofi-aventis U.S. LLC | 5 | $112 |
| Kowa Pharmaceuticals America, Inc. | 5 | $103 |
| Neurocrine Biosciences, Inc. | 3 | $74 |
| Recordati_rare_diseases_inc. | 3 | $67 |
| Avanir Pharmaceuticals, Inc. | 4 | $65 |
| Insulet Corporation | 3 | $60 |
| Averitas Pharma Inc. | 2 | $57 |
| Ultragenyx Pharmaceutical Inc. | 3 | $57 |
| Boehringer Ingelheim | 2 | $42 |
| Nevro Corp. | 2 | $38 |
| Sequel Med Tech, LLC | 1 | $29 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Exact Sciences | 1 | $25 |
| Edwards Lifesciences | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$104
How this compares
$9,567 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $43,138 |
| JardianceEmpagliflozin | 22 | $26,649 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $11,267 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $4,467 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,521 |
| Novolog FlexpenInsulin Aspart | 11 | $2,296 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,675 |
| Ezetimibe | 58 | $1,294 |
| SynthroidLevothyroxine Sodium | 21 | $1,023 |
| UnithroidLevothyroxine Sodium | 28 | $906 |
| Rosuvastatin Calcium | 38 | $858 |
| Levothyroxine Sodium | 59 | $758 |
| Pravastatin Sodium | 35 | $745 |
| Metformin Hcl ErMetformin Hcl | 41 | $686 |
| Montelukast Sodium | 40 | $601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $531 | $43,13827 claims |
| Boehringer IngelheimJardiance | $42 | $26,64922 claims |
| GSKTrelegy Ellipta | $294 | $11,26719 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $1,223 | $1,66487 claims |
| AbbVieSynthroid | $962 | $1,02321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Beaver
- Beth SandyPhiladelphia$924K
- Jennifer MondilloSchwenksville$396K
- Diane NewmanPhiladelphia$343K
- Elizabeth FaustDouglassville$342K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
- Catherine HoldsworthPhiladelphia$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.